Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
AGPAT2 encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. Additionally we are shipping AGPAT2 Kits (14) and AGPAT2 Proteins (4) and many more products for this protein.
Showing 10 out of 42 products:
Human Polyclonal AGPAT2 Primary Antibody for EIA, WB - ABIN4620346
West, Tompkins, Balantac, Nudelman, Meengs, White, Bursten, Coleman, Kumar, Singer, Leung: Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine-induced signaling responses in cells. in DNA and cell biology 1997
Show all 6 references for ABIN4620346
Human Polyclonal AGPAT2 Primary Antibody for WB - ABIN2781951
Niesporek, Denkert, Weichert, Köbel, Noske, Sehouli, Singer, Dietel, Hauptmann: Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis. in British journal of cancer 2005
Data show that missense mutation c.299G>A changes serine in the acyltransferase NHX4D motif of AGPAT2, and intronic c.493-1G>C mutation destroy a splicing site that leads to exon 4 skipping and deletion of whole AGPAT2 substrate binding domain.
the ability of LPAAT-beta to regulate mTOR (show FRAP1 Antibodies) function
miR (show MLXIP Antibodies)-24 may play an important role in inhibiting osteosarcoma growth through suppression of LPAATbeta.
Data suggest that AGPAT2 regulates adipogenesis through modulation of lipid metabolism/signal transduction, altering normal activation of phosphatidylinositol 3-kinase (PI3K (show PIK3CA Antibodies))/protooncogene c-Akt (show AKT1 Antibodies) and PPARgamma (show PPARG Antibodies) signaling in early stage of adipogenesis.
the role of AGPAT1 (show AGPAT1 Antibodies) or AGPAT2 in liver lipogenesis is minimal and that accumulation of liver fat is primarily a consequence of insulin (show INS Antibodies) resistance
lpaat beta gene overexpression exists in both AML (show RUNX1 Antibodies) and CML (show BCR Antibodies) patients. lpaat beta produced by AML (show RUNX1 Antibodies) cells probably plays an important role in abnormal proliferation and drug-resistance of AML (show RUNX1 Antibodies) cells.
Lysophosphatidic acid acyltransferase beta (LPAATbeta) promotes the tumor growth of human osteosarcoma
AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.
Congenital lipodystrophy patients with Seipin (show BSCL2 Antibodies) mutations have a more severe lack of body fat, which affects both metabolically active and mechanical adipose tissue, compared with patients with mutations in the AGPAT2 gene.
mutations in AGPAT2 and Gng3lg (show BSCL2 Antibodies) are approximately equally represented in congenital generalized lipodystrophy
Data indicate that the longissimus dorsi muscle (LM) of steers showed higher G0/G1 switch gene 2 (G0S2 (show G0S2 Antibodies)) and comparative gene identification-58 (CGI-58 (show ABHD5 Antibodies)) mRNA expression levels than the LM of bulls.
Adipogenically induced Agpat2(-/-) preadipocytes had fewer lipid-loaded cells and lower levels of adipocyte markers than wild type preadipocytes.
Leptin (show LEP Antibodies) ameliorates insulin (show INS Antibodies) resistance and hepatic steatosis in Agpat2-/- lipodystrophic mice independent of hepatocyte leptin (show LEP Antibodies) receptors
The lack of normal insulin (show INS Antibodies) signaling in Agpat2(-/-) livers allows unrestricted phosphatidic acid-induced gluconeogenesis.
Data suggest that Agpat2 regulates adipogenesis through modulation of lipid metabolism/signal transduction, altering normal activation of phosphatidylinositol 3-kinase (PI3K)/protooncogene c-Akt (show AKT1 Antibodies) and PPARgamma (show PPARG Antibodies) signaling in early stage of adipogenesis.
Loss of adipocytes by necrosis and apoptosis in Agpat2 null mice
impaired AGPAT2 activity affects availability of phosphatidic acid (PA) for triacylglycerol synthesis but not overall PA synthesis nor utilization of PA for phospholipid synthesis
The alternative monoacylglycerol pathway for triglyceride biosynthesis is activated in the absence of 1-acylglycerol-3-phosphate O-acyltransferase 2.
This gene encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in this gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta)
, 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha
, 1-AGP acyltransferase 2
, 1-AGPAT 2
, 1-acyl-sn-glycerol-3-phosphate acyltransferase beta
, lysophosphatidic acid acyltransferase beta
, lysophosphatidic acid acyltransferase-beta
, lysophosphatidic acid acyltransferase, beta